The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Emergent Biosolutions Inc (NYSE: EBS) closed the day trading at $8.91 up 9.19% from the previous closing price of $8.16. In other words, the price has increased by $9.19 from its previous closing price. On the day, 1.94 million shares were traded. EBS stock price reached its highest trading level at $9.13 during the session, while it also had its lowest trading level at $8.255.
Ratios:
For a better understanding of EBS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.07. For the most recent quarter (mrq), Quick Ratio is recorded 3.00 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 1.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 12 ’25 when DONALD DEGOLYER bought 7,844 shares for $8.65 per share.
Katkin Keith sold 7,844 shares of EBS for $49,417 on May 23 ’25. The Director now owns 86,431 shares after completing the transaction at $6.30 per share. On May 23 ’25, another insider, KEITH KATKIN, who serves as the Director of the company, bought 7,844 shares for $6.30 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 475358304 and an Enterprise Value of 884158272. As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.63, and their Forward P/E ratio for the next fiscal year is 9.28. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.56 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at 1.038 whereas that against EBITDA is 4.078.
Stock Price History:
The Beta on a monthly basis for EBS is 2.00, which has changed by 0.17701459 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.28, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 31.07%, while the 200-Day Moving Average is calculated to be 18.50%.
Shares Statistics:
Over the past 3-months, EBS traded about 1.32M shares per day on average, while over the past 10 days, EBS traded about 1878720 shares per day. A total of 53.70M shares are outstanding, with a floating share count of 51.04M. Insiders hold about 4.34% of the company’s shares, while institutions hold 70.40% stake in the company. Shares short for EBS as of 1753920000 were 9947951 with a Short Ratio of 7.53, compared to 1751241600 on 10007823. Therefore, it implies a Short% of Shares Outstanding of 9947951 and a Short% of Float of 18.84.
Earnings Estimates
The stock of Emergent Biosolutions Inc (EBS) is currently in the spotlight, with 1.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.21, with high estimates of $0.21 and low estimates of $0.21.
Analysts are recommending an EPS of between $1.19 and $1.19 for the fiscal current year, implying an average EPS of $1.19. EPS for the following year is -$1.9, with 1.0 analysts recommending between -$1.9 and -$1.9.
Revenue Estimates
3 analysts predict $203.67M in revenue for the current quarter. It ranges from a high estimate of $213M to a low estimate of $198M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $293.8MFor the next quarter, 3 analysts are estimating revenue of $233.67M. There is a high estimate of $251M for the next quarter, whereas the lowest estimate is $220M.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $828.28M, while the lowest revenue estimate was $783.1M, resulting in an average revenue estimate of $800.83M. In the same quarter a year ago, actual revenue was $1.04BBased on 2 analysts’ estimates, the company’s revenue will be $918.74M in the next fiscal year. The high estimate is $1.16B and the low estimate is $682.47M.
